Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Ossenkoppele, G.J.
501  Ergebnisse:
Personensuche X
?
1

Determinants of lenalidomide response with or without eryth..:

van de Loosdrecht, A. A. ; Cremers, E. M. P. ; Alhan, C....
Leukemia.  38 (2024)  4 - p. 840-850 , 2024
Link: https://doi.org/10.1038/..
 
?
2

Addition of the nuclear export inhibitor selinexor to stand..:

Janssen, J. J. W. M. ; Löwenberg, B. ; Manz, M....
Leukemia.  36 (2022)  9 - p. 2189-2195 , 2022
Link: https://doi.org/10.1038/..
 
?
3

P406: ENHANCED SIGNIFICANCE OF FLT3-ITD RESIDUAL DISEASE DE..:

Grob, T. ; Sanders, M. ; Vonk, C....
HemaSphere.  6 (2022)  - p. 306-307 , 2022
Link: https://doi.org/10.1097/..
 
?
4

Evaluating ivosidenib for the treatment of acute myeloid le..:

Donker, M. L. ; Ossenkoppele, G. J.
Expert Opinion on Pharmacotherapy.  21 (2020)  18 - p. 2205-2213 , 2020
Link: https://doi.org/10.1080/..
 
?
5

Correction: Lenalidomide added to standard intensive treatm..:

Ossenkoppele, G. J. ; Breems, D. A. ; Stuessi, G....
Leukemia.  34 (2020)  10 - p. 2820-2820 , 2020
Link: https://doi.org/10.1038/..
 
?
6

Lenalidomide added to standard intensive treatment for olde..:

Ossenkoppele, G. J. ; Breems, D. A. ; Stuessi, G....
Leukemia.  34 (2020)  7 - p. 1751-1759 , 2020
Link: https://doi.org/10.1038/..
 
?
7

Improved survival for children and young adolescents with a..:

Reedijk, A. M. J. ; Klein, K. ; Coebergh, J. W. W....
Leukemia.  33 (2018)  6 - p. 1349-1359 , 2018
Link: https://doi.org/10.1038/..
 
?
8

Distinct factors determine the kinetics of disease relapse ..:

Craddock, C. ; Versluis, J. ; Labopin, M....
Journal of Internal Medicine.  283 (2018)  4 - p. 371-379 , 2018
Link: https://doi.org/10.1111/..
 
?
9

Response to letter commenting on: Prognostic relevance of m..:

van Spronsen, M.F. ; Witte, B.I. ; Ossenkoppele, G.J...
European Journal of Cancer.  72 (2017)  - p. 269-271 , 2017
Link: https://doi.org/10.1016/..
 
?
10

In silico and preclinical drug screening identifies dasatin..:

Laukkanen, S ; Grönroos, T ; Pölönen, P...
Blood Cancer Journal.  7 (2017)  9 - p. e604-e604 , 2017
Link: https://doi.org/10.1038/..
 
?
11

Measurable residual disease testing in acute myeloid leukae..:

Hourigan, C S ; Gale, R P ; Gormley, N J..
Leukemia.  31 (2017)  7 - p. 1482-1490 , 2017
Link: https://doi.org/10.1038/..
 
?
12

Treatment and outcome of 2904 CML patients from the EUTOS p..:

Hoffmann, V S ; Baccarani, M ; Hasford, J...
Leukemia.  31 (2016)  3 - p. 593-601 , 2016
Link: https://doi.org/10.1038/..
 
?
13

Comparative value of post-remission treatment in cytogeneti..:

Versluis, J ; in 't Hout, F E M ; Devillier, R...
Leukemia.  31 (2016)  1 - p. 26-33 , 2016
Link: https://doi.org/10.1038/..
 
?
14

Autologous stem cell transplantation (ASCT) in patients wit..:

Cook, G. ; Iacobelli, S. ; van Biezen, A....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e57-e58 , 2015
Link: https://doi.org/10.1016/..
 
?
15

Frontline nilotinib in patients with chronic myeloid leukem..:

Hochhaus, A ; Rosti, G ; Cross, N C P...
Leukemia.  30 (2015)  1 - p. 57-64 , 2015
Link: https://doi.org/10.1038/..
 
1-15